458 related articles for article (PubMed ID: 33967605)
1. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
2. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
3. Repurposing infectious disease vaccines for intratumoral immunotherapy.
Melero I; Gato M; Shekarian T; Aznar A; Valsesia-Wittmann S; Caux C; Etxeberrria I; Teijeira A; Marabelle A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32102830
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
Huang Z; Liu M; Huang Y
Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
[TBL] [Abstract][Full Text] [Related]
6. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
7. Safety and clinical usage of newcastle disease virus in cancer therapy.
Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
12. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Zamarin D; Holmgaard RB; Subudhi SK; Park JS; Mansour M; Palese P; Merghoub T; Wolchok JD; Allison JP
Sci Transl Med; 2014 Mar; 6(226):226ra32. PubMed ID: 24598590
[TBL] [Abstract][Full Text] [Related]
13. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
[TBL] [Abstract][Full Text] [Related]
14. Recombinant infectious bursal disease virus expressing Newcastle disease virus (NDV) neutralizing epitope confers partial protection against virulent NDV challenge in chickens.
Li K; Gao L; Gao H; Qi X; Gao Y; Qin L; Wang Y; Wang X
Antiviral Res; 2014 Jan; 101():1-11. PubMed ID: 24200519
[TBL] [Abstract][Full Text] [Related]
15. Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.
Schirrmacher V
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28531117
[TBL] [Abstract][Full Text] [Related]
16. Advancement in vaccination against Newcastle disease: recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions.
Palya V; Kiss I; Tatár-Kis T; Mató T; Felföldi B; Gardin Y
Avian Dis; 2012 Jun; 56(2):282-7. PubMed ID: 22856183
[TBL] [Abstract][Full Text] [Related]
17. Heterologous prime-boost immunization of Newcastle disease virus vectored vaccines protected broiler chickens against highly pathogenic avian influenza and Newcastle disease viruses.
Kim SH; Samal SK
Vaccine; 2017 Jul; 35(33):4133-4139. PubMed ID: 28668574
[TBL] [Abstract][Full Text] [Related]
18. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases.
Duan Z; Xu H; Ji X; Zhao J
Future Microbiol; 2015; 10(8):1307-23. PubMed ID: 26234909
[TBL] [Abstract][Full Text] [Related]
20. Development of a novel thermostable Newcastle disease virus vaccine vector for expression of a heterologous gene.
Wen G; Chen C; Guo J; Zhang Z; Shang Y; Shao H; Luo Q; Yang J; Wang H; Wang H; Zhang T; Zhang R; Cheng G; Yu Q
J Gen Virol; 2015 Jun; 96(Pt 6):1219-1228. PubMed ID: 25626679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
